Equillium Q2 FY26 net loss narrows to USD 4.7 million; cash slips to USD 57.2 million
EQ•Cash position and pipeline updates
Cash and cash equivalents totaled USD 57.2 million at June 30, 2026; management expects funding runway into 2029.
The Phase 1 proof-of-mechanism study of EQ504 is expected to start in Q4 2026, with topline data targeted about six months later.
IND-enabling work began for inhaled EQ504 in inflammatory lung disease and for EQ302, an oral IL-15/IL-21 inhibitor for celiac disease.
Q2 loss narrows as expenses diverge
Equillium posted a net loss of USD 4.7 million, or USD 0.04 per share, in Q2 2026, narrowing from a USD 5.7 million loss.
R&D expense fell 31.44% to USD 2.8 million, while G&A expense rose 12.17% to USD 2.4 million.
Related News
Lululemon Athletica - Ranju Das Ceases To Serve As Chief AI & Technology Officer As Of August 13, 2026
LULU•
TMC publishes investor deck outlining NOAA permitting progress for U.S. deep-sea nodule project in CCZ
TMC•
